
LEO Pharma Announces Positive Preliminary Phase 2b Findings for Temtokibart in Atopic Dermatitis
Temtokibart (LEO 138559), an investigational monoclonal antibody targeting the IL-22RA1 receptor subunit, achieved statistically significant improvements in eczema severity at the 3 highest tested doses in a phase 2b clinical trial of adults with moderate- …